Equibles does not estimate personal net worth.
Get an email with a short summary when Phathom Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get PHAT alertsSteven Basta is recorded as Board Member and CEO at Phathom Pharmaceuticals, Inc. (PHAT) since April 1, 2025. The newest filing on record that lists Steven Basta as Board Member and CEO at Phathom Pharmaceuticals, Inc. (PHAT) is dated April 7, 2026. Phathom Pharmaceuticals, Inc. reported in an 8-K filed April 1, 2025 that Steven Basta was appointed Class I director, effective April 1, 2025. Phathom Pharmaceuticals, Inc. reported in an 8-K filed April 1, 2025 that Steven Basta was appointed President, effective April 1, 2025. Phathom Pharmaceuticals, Inc. reported in an 8-K filed April 1, 2025 that Steven Basta was appointed Chief Executive Officer, effective April 1, 2025. The proxy statement of Phathom Pharmaceuticals, Inc. reports total compensation of $6,968,070 for Steven Basta in fiscal 2025, including a base salary of $525,000. Steven Basta has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Phathom Pharmaceuticals, Inc. on April 30, 2026. Phathom Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Phathom Pharmaceuticals, Inc. includes Steven L. Basta (CEO and Board Member), Anthony Guzzo (CFO and Chief Accounting Officer), Sanjeev Narula (CFO) and 7 others.
“Effective April 1, 2025, Steven Basta was appointed as the Chief Executive Officer, President and as a Class I director of Phathom Pharmaceuticals, Inc. (the "Company"), replacing Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") for personal reasons, effective March 31, 2025.”
“Effective April 1, 2025, Steven Basta was appointed as the Chief Executive Officer, President and as a Class I director of Phathom Pharmaceuticals, Inc. (the "Company"), replacing Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") for personal reasons, effective March 31, 2025.”
“And thank you, everyone, for joining our call this morning. Let me start with a few highlights and a bit of perspective on the quarter. we more than doubled revenue from Q1 2025 to Q1 2026.”
“Let me just sort of briefly touch on company history and then talk about strategy today and then sort of updates. So Fathom has a commercial product, which is Vaquesna, which is the next generation treatment for gastroesophageal reflux.”
2025-04-01–present
Last confirmed April 7, 2026
2025-04-01–present
Last confirmed April 7, 2026
2025-04-01–present
Biotechnology · Healthcare
Board Member, CEO
2025-04-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Phathom Pharmaceuticals, Inc. (PHAT) | President and Chief Executive Officer | $525,000 | $6,968,070 |
